Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy-Reference-Cited by-同舟云学术

Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy

Published:2022-09 Issue:3 Volume:166 Page:522-529
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Barrington David A.,Calo Corinne,Baek Jae,Brown Morgan,Wagner Vincent,Gonzalez Lynette,Huffman Allison,Benedict Jason,Bixel Kristin

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference42 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009;Makker;Int. J. Gynecol. Cancer,2013

3. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study;Muggia;J. Clin. Oncol.,2002

4. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study;Aghajanian;J. Clin. Oncol.,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis;Gynecologic Oncology;2024-02

2. Reanalysis of single-cell data reveals macrophage subsets associated with the immunotherapy response and prognosis of patients with endometrial cancer;Experimental Cell Research;2023-09

3. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors;Frontiers in Immunology;2023-07-10